FIELD: medicine. SUBSTANCE: the innovation in question deals with medicinal preparation containing CoA-thioethers of arylpropionic acids, arylacetic acids or acetylsalicylates, R-ibuprofen or ibuprofen racemates containing up to 49% S-ibuprofen, or derivatives of the above-mentioned compounds similarly metabolized in the body. The innovation should be used for indications of acute or/and chronic pain, inflammations of any origin and for counteraction to all other symptoms of inflammatory processes. The suggested medicinal preparation prevents prostaglandins' synthesis as a result of inflammatory processes. EFFECT: higher efficiency. 5 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| EMPLOYMENT OF (R)-ARYLPROPIONIC ACIDS TO PREPARE DRUGS FOR TREATMENT OF HUMANS AND ANIMALS LIABLE TO BE THERAPEUTICALLY AFFECTED VIA NF-κB ACTIVATION INHIBITION | 2000 |
|
RU2250103C2 |
| AGENT FOR PAIN OR INFLAMMATION TREATMENT | 1991 |
|
RU2080116C1 |
| METHOD FOR DETERMINING SHOCK STATE AND CONTROLLING PATIENT TREATMENT PROCESS IN THE SHOCK STATE | 1995 |
|
RU2164026C2 |
| SOLUTIONS AND METHODS FOR INHIBITING PAIN, CARTILAGE INFLAMMATION AND DESTRUCTION | 2000 |
|
RU2271825C2 |
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| METHOD FOR INHIBITING NUCLEAR FACTOR KAPPA B WITH USE OF 5-HYDROXYNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE IN CELL CULTURE | 2017 |
|
RU2674443C1 |
| (R)-2-ARYLPROPIONIC ACID OMEGA-AMINOALKYLAMIDES AS INHIBITORS OF POLYMORPHONUCLEAR AND MONONUCLEAR CELL HEMOTAXIS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2272024C2 |
| NEW TREATMENT OF MULTIPLE SCLEROSIS (MS) | 2011 |
|
RU2595861C2 |
| AMIDINE DERIVATIVE SALTS AND CYCLOOXYGENASE INHIBITOR, METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 1996 |
|
RU2167856C2 |
| NSAIDS APPLICATION IN EXCIMER LASER CORNEAL SURGERY | 2015 |
|
RU2612810C2 |
